Editas Medicine
EDIT
193 hedge funds and large institutions have $983M invested in Editas Medicine in 2019 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 62 increasing their positions, 48 reducing their positions, and 33 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
29% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 48
7% more capital invested
Capital invested by funds: $917M → $983M (+$66.7M)
4.41% more ownership
Funds ownership: 76.36% → 80.77% (+4.4%)
4% less funds holding
Funds holding: 201 → 193 (-8)
12% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 33
42% less call options, than puts
Call options by funds: $8.51M | Put options by funds: $14.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
+$56.6M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$18.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.48M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$6.89M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$6.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$24.5M |
| 2 |
Renaissance Technologies
New York
|
-$9.08M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$7.59M |
| 4 |
OTPPB
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
|
-$7.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.04M |
EDIT Hedge Fund Activity: Q2 2019 in Review
193 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q2 2019, worth a combined $983M — up 7.3% from $917M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of EDIT and 29 opened new positions — a net loss of 4 holders — while 48 trimmed existing stakes and 62 added.
The largest buyer was Nikko Asset Management Americas, adding an estimated $56.6M. The largest seller was Morgan Stanley, cutting an estimated $24.5M.
- 193 institutional investors held Editas Medicine (EDIT) as of Q2 2019, down from 201 in Q1 2019.
- Funds reported $983M of Editas Medicine stock for Q2 2019, up 7.3% quarter-over-quarter.
- 29 funds opened new Editas Medicine positions in Q2 2019 and 33 closed out, a net change of -4 holders.
- The largest Editas Medicine buyer in Q2 2019 was Nikko Asset Management Americas, an estimated $56.6M added.
- The largest Editas Medicine seller in Q2 2019 was Morgan Stanley, an estimated $24.5M sold.
Based on aggregated 13F filings for Q2 2019.